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Abstract
Actions of the new antiepileptic drug lamotrigine (LTG) were characterized
using extracellular and whole cell patch clamp recordings from rat CA1 and
CA3 pyramidal cells in vitro. The results suggest that LTG, beside its previously
described effect on the fast sodium inward current, also modulates – presum-
ably voltage-gated – calcium currents and the transient potassium outward
current ID . These may be effective mechanisms to inhibit pathological excita-
tion in epilepsy and may be of potential benefit in treating underlying cellular
disturbances in bipolar disorder.
.......................
Introduction of bipolar disorder, both in manic and depressed episodes
[9]. Another approach to limit hyperexcitability is a
modulation of potassium currents. Recently, the impor-Lamotrigine (LTG; 3,5-diamino-6-(2,3 dichlorphenyl)-
1,2,4-triazine) is a clinically useful antiepileptic drug, tant impact of potassium-dependent repolarization for
age-specific epilepsies has been demonstrated [10]. Themainly administered as an add-on medication to other
anticonvulsants in therapy resistant epilepsy [1]. Due to fast transient potassium outward current (IA) counteracts
depolarization of a neuron. So far, an increase of thisreported efficacy in single case observations [2–4] it is
also gaining increasing interest as a potential mood stabi- current has been demonstrated for valproate [11] and
CBZ [12].lizer in psychiatry. Similar to other antiepileptic drugs,
e.g. carbamazepine (CBZ) and phenytoin, a blockade of Most antiepileptic drugs which act on the level of ion
channels do not exert just one specific blockade. Forvoltage-dependent sodium channels [5] mainly in their
inactivated state [6] has been demonstrated so far. Fur- example, both valproate and CBZ show actions on
voltage-gated sodium, calcium and potassium channelsthermore, LTG exerts cell-protective effects by decreasing
glutamate release in the striatum [7]. Beside a high sodium [12–15]. All of these excitation-limiting effects may be of
potential value in treating both epilepsies and bipolarinflux and elevated glutamate release, an increase of the
intracellular calcium concentration has been suggested as disorder. Our electrophysiological in vitro experiments
were designed to test whether LTG is also capable ofan underlying disturbance both in epilepsies and bipolar
disorder [8]. Based on this rationale, calcium antagonists modulating calcium and potassium currents in hippocam-
pal neurons beside its known action on sodium channels.have been tested partially successfully for the treatment
Ó1998 S. Karger AG, Basel Heinz Grunze, MD
0302–242X/98/0383–0131$15.00/0 Psychiatrische Klinik der Universita¨t
Nussbaumstrasse 7, D–80336 Mu¨nchen (Germany)Fax+41 61 306 12 34
Accessible online at: Tel. +49 89 51605335, Fax +49 89 51605330E-Mail karger@karger.ch
www.karger.ch http://BioMedNet.com/karger E-Mail grunze@psy.med.uni-muenchen.de
Fig. 1. LTG reduces extracellular field po-
tentials induced by omission of Mg2+ from the
extracellular bath solution. Recordings before
(baseline), 30 min during and 60 min after
(wash-out) thesuperfusionwith20 lmol/l (A),
5 lmol/l (B) and 1 lmol/l LTG (C).
A
B
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Fig. 2. Effects of combinations of sub-
threshold concentrations of LTG with sub-
threshold concentrations with CBZ (A),
VERA (B) and 5-aminophosphonovalerate
(APV; C).
A
B
C
4, CaCl2 0.75, KH2 PO4 1.24, MgCl2 1.3, NaHCO3 26, and glucoseMethods
10. Slices were kept at 28 ºC and equilibrated with 5% CO in O2 (pH
7.35–7.4) throughout the preincubation and recording period. AfterExtracellular Recordings
placing a slice in the recording chamber and switching to ACSFExtracellular recordings of spontaneous, rhythmic excitatory field
without Mg2+, spontaneous EFPs developed in the hippocampal CA3potential (EFP) bursts in low Mg2+ artificial cerebrospinal fluid
and CA1 area. To increase epileptic activity, potassium concentration(ACSF) are a convenient method to screen substances for calcium
was elevated from 4 to 8 mmol/l in some recordings. Recordings wereantagonistic properties. Several investigations have shown that calcium
made with borosilicate electrodes containing 2 mmol/l NaCl. Thecurrents essentially contribute to the generation of these EFPs [16, 17].
signals were amplified by a conventional microelectrode amplifierReduction or omission of Mg2+ induces EFPs by increasing the trans-
from NPI electronics, stored on an oscilloscope and plotted on a chartmembraneous calcium flux into the cell. Hitherto, suppression of
recorder. Results are given as mean×SE.EFPs indicates calcium antagonistic properties of a substance (for
details of this rationale, see [17]).
Our experiments [18] were performed in hippocampal slices of Intracellular Recordings
In order to characterize the effect of LTG on the early transientguinea pigs (weight 350–550 g, both genders). After removing the
brain under ether anesthesia, transverse hippocampal slices of potassium outward current, we performed whole cell patch clamp and
voltage clamp recordings from CA 1 pyramidal neurons in a hippocam-350–500 lM were cut. The ionic composition of the ACSF during
pre-incubation of the slices for 1 h was (in mmol/l): NaCl 124, KCl pal slice preparation from Long-Evans rats (20–30 days, both genders).
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Harvesting of slices was done as described above. Slices were placed in
a recording chamber continuously superfused with ACSF containing
(in mmol/l): NaCl 124, KCl 3.75, KH2PO4 1.25, MgCl2 1.3, CaCl2 2.5,
NaHCO3 26, glucose 10. The ACSF was bubbled with 95% O2 /5% CO2
and maintained at 30×2 ºC throughout the recordings. The recordings
were obtained with borosilicate glass electrodes (resistance 4–6 MX)
filled with (in mmol/l): K-citrate 120, CaCl2 1, MgCl2 3, MaATP 2,
NaGTP 2, EGTA 3 and HEPES 40 (modified from Blanton et al. [19]).
In voltage-clamp recordings, tetrodotoxin (TTX) 0.6 lmol/lwas added
to the ACSF and in two experiments, tetraethylammonium chloride
(TEA) 10 mmol/l was also added. LTG was dissolved in 0.3% DMSO
(final concentration), which, in control experiments, had no effect on
the electrophysiological properties, and was administered systemically
with the ACSF. Both voltage clamp and current clamp recordings, using
a bridge circuit, were made with an Axoclamp 2A amplifier (Axon In-
struments, Burlingame, Calif., USA). Data were collected standardized
at baseline, after a 30-min wash-in period of LTG and after a 30-min
wash-out. Results are given in percent of change×SE.
Experiments were only conducted on cells with a resting membrane
potential of 58 mV and above (range in all cells considered for experi-
ments 58–65 mV), their input resistance was between 50 and 100 MX.
These parameters were monitored for stability at the beginning and
after a 30-min wash-out at the end of the experiment.
Differences in the species used and the composition of the ACSF
are explained by the fact that extra- and intracellular recordings were
conducted independently in two different laboratories. Drugs used
were supplied from Sigma except for LTG (Glaxo-Wellcome, England)
and CBZ (Desitin Arzneimittel GmbH, Germany).
Results
Extracellular Recordings
After switching the slice to a zero Mg2+ solution typi-
cal EFPs developed spontaneously within a few minutes
(fig. 1, baseline) resembling the extracellular correlate of
intracellular paroxysmal depolarization shifts [13, 14, 20].
The discharge rate of EFP in 8 mmol/l K+ in the ACSF
was in the range of 21–88/min (n>19) with no difference
between the CA3 and CA1 region of the hippocampal
Fig. 3. 100 lM LTG reduces neuronal excitability in a wholeslice [16].
cell patch clamp recording of a pyramidal CA1 neurone. Left trace:
When LTG 10 lmol/l was added, EFP were reduced Response to 150 pA current input, duration 250 ms, holding potential
both in amplitude and frequency up to a total suppres- –60 mV. Right trace: Response to 850 pA current input, duration
sion after 20–40 min. Typical experiments with 20, 5 and 10 ms, holding potential –60 mV. A Baseline. B After 30-min LTG
(100 lM ). C After 30-min wash-out. D Overlap of A and B, right1 lmol/l LTG are depicted in figure 1. A similar decline
traces.of EFP rates as with 20 lmol/l LTG was observed in prior
A
B
C
D
experiments where CBZ (50 lmol/l) or verapamil (VERA,
20 lmol/l) was added to the ACSF (cf. Walden et al. [13]).
The effect of LTG on low-Mg2+-induced EFP showed With 1 lmol/l LTG, no effect on the EFP rate could
be observed. This concentration of 1 lmol/l of LTG wasdose-dependency with an EFP rate reduction for 5 lmol/l
LTG to 0.22×0.24 (n>5) and to 0.51×0.08 (n>6) for considered as a subthreshold concentration (fig. 1C). Sim-
ilar, subthreshold concentrations evaluated in earlier ex-2 lmol/l LTG. Following withdrawal of LTG from the
ACSF, the baseline EFP rates were fully restored within periments were 2 lmol/l for VERA and 10 lmol/l for
CBZ [13, 14]. To investigate the additive effects of LTG56–82/min.
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Fig. 4. Voltage clamp recordings, 100 lM
LTG, TTX 0.6 lM, HP –80 mV. A Baseline
response to depolarizing voltage steps of
10–40 mV. B After 30-min LTG. C Overlap of
A and B, response to a +40 mV step.
A B
C
with CBZ and VERA, the subthreshold concentration of (n>4; fig. 2C), making the NMDA receptor unlikely as
the primary site of action for LTG.1 lmol/l LTG was administered either with the subthresh-
old concentration of 10 lmol/l CBZ or the subthreshold
concentration of 2 lmol/l VERA. These combinations Intracellular Recordings
Bridge Mode Recordings. A depolarizing current wasreduced the EFP rate to 0.62×0.32 (n>8) for LTG with
CBZ (fig. 2A) and to 0.34×0.14 (n>6) for LTG with injected through the recording electrode (150–950 pA,
250 ms), starting from a holding potential of –60 mV,VERA (fig. 2B).
Since removal of the magnesium block of the postsyn- eliciting a high-frequency train of action potentials (AP).
LTG (25 lmol/l, administered systemically with theaptic NMDA receptor is one mechanism involved in the
generation of low-Mg2+-induced field potential changes ACSF for 30 min, n>7) neither effected input resistance,
nor AP threshold and AP duration. Maximal spiking[17] the effect of the NMDA antagonist 5-aminophos-
phonovalerate (APV) on the EFP repetition rate was frequency at 150 pA was reduced by –36×27% (range
–67K0%, pp0.025, Mann-Whitney test). Although LTGtested. APV reduced the frequency of occurrence of EFP
in a dose-dependent manner. The subthreshold concen- had no effect on the AP amplitude of the first spike, it
caused a nonsignificant trend of reversibly decreasingtration of APV without effects on the EFP rate turned
out to be 0.5 lmol/l. However, combining subthreshold the AP amplitude of the second spike (–5×6%). These
findings can be explained with the previously describedconcentration of 1 lmol/l LTG with the subthreshold
concentration of 0.5 lmol/l APV was without effect inhibition of fast sodium channels [4, 5, 10]. In 5/7 cells,
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an increase of the latency from current input to AP thresh-
old of the first spike (Dtc–tAP) was observed (21×16%,
range 42K0%). All of these changes were only partially
reversible within 30-min wash-out.
Increasing the concentration, LTG (100 lmol/l, n>6)
diminished the first AP amplitude by 13×11% (pp0.025),
and reduced the AP frequency for given current steps
(–43×20% at 350 pA, –42×9% at 150 pA, both signifi-
cant at pp0.025). Further analysis showed that this was
caused by a reversible increase of the interspike interval
with unchanged AP duration. Dtc–tAP was also increased
by 55×37% (pp0.025) at 150 pA (fig. 3). This observa-
tion was backed up by 2 further recordings from a holding
potential of –75 mV showing a clear-cut increase of Dtc–tAP .
Voltage Clamp Recordings. These effects were a hint
pointing towards a modulation of the fast transient potas-
sium outward current. Accordingly, voltage clamp analy-
sis was performed in 8 neurons after addition of TTX
(0.6 lmol/l). From a holding potential of –80 mV, depo-
larizing voltage steps from 10 to 40 mV were conducted.
6/8 neurons showed an increase of a transient outward
current, activated instantly and lasting for more than
200 ms, observed with a step command of +40 mV in
the presence of 100 lmol/l LTG (fig. 4). Again, this in-
crease was only partially reversible within a 30-min wash-
out period. To exclude an effect of DMSO by itself, three
cells were recorded under similar conditions, adding only
0.3% DMSO. No changes were observed under this condi-
Fig. 5. Voltage clamp recordings, 100 lM LTG, TTX 0.6 lM,tion.
TEA 10 mM, HP –80 mV. Magnification of the early componentsTo ensure that this finding was not due to an increase
(t from 0 to 100 ms) shows again the increase of the fast, non-TEA-of the delayed rectifier, we added TEA 10 mmol/l together
sensitive transient outward current. Solid line>baseline; large dots>
with TTX at baseline (n>2 neurons). As a result, we LTG for 20 min; small dots>after a 30-min wash-out.
obtained a similar increase of the early current com-
ponent which was again only partially reversible after a
30-min wash-out (fig. 5).
Analysis of all 8 neurons (fig. 6A) showed that this ID (fig. 6D). At this point, it remains undetermined
whether this is a true increase or a shift of its steadyearly current consists of an instantly activating and
rapidly declining component (fig. 6B) and a second com- state inactivation function, which still has to be further
characterized.ponent, activated within a short delay and lasting for
more than 150 ms (fig. 6C). This appears characteristic
for IA and ID , respectively [21]. These currents are closely
related and co-existing fast transient potassium outward Discussion
currents which are, in contrast to the delayed rectifier,
not sensitive to TEA. Averaging over all 8 neurons and In the experiments presented here it was found that
the new antiepileptic drug LTG reduced dose-depend-extrapolating to t>0 showed an increase of current in
LTG by 193 pA for the early component made of both ently the repetition rate of extracellular field potentials
in the low-magnesium model of epilepsy. The additionIA and ID . Subtracting the extrapolated ID component at
t>0, based on the current between 50 and 150 ms after of subthreshold concentrations of LTG and the organic
calcium antagonist VERA or the antiepileptic drug CBZ,IA inactivation, reveals that the current increase caused
by LTG is almost exclusively due to an enhancement of respectively, also led to a reduction of the frequency of
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Fig. 6. A Plots of log I (pA)Öt (ms) for the
mean current of all 4 neurons in response to
a+30 mV step (–80K–50 mV). I(BL)>Con-
trol before LTG application; I(LTG)>after
30 min application of 100 lM LTG. B Linear
regression for the interval 10–40 ms to extra-
polate for the IA component at t>0. C Linear
regression for the interval 50–150 ms to extra-
polate for the ID component at t>0. D Sub-
traction of the slow component ID from the
fast component IA both for LTG and control
reveals that there is no significant contribution
of IA . The overall increase of current is almost
exclusively due to an increase of ID .
A
B C
D
occurrence of zero-Mg2+-induced field potentials. The Clinical effects of LTG require steady state plasma con-
centrations of about 4–16 lmol/l. However, some patientszero-Mg2+ model is thought to cause epileptiform dis-
charges due to increased transmembraneous calcium ion with epilepsy may need concentrations up to 40 lmol/l
[29]. Because 55% of the total LTG in humans is bound tofluxes and it is blocked by organic calcium channel inhib-
itors, e.g. VERA [13, 16, 22]. In concentrations as used plasma proteins, the free concentration range is estimated
between 2 and 20 lmol/l which corresponds to the concen-in the present investigation, VERA specifically blocks L-
type calcium channels, but fails to alter other membrane trations used in the extracellular experiments. In intra-
cellular experiments, higher concentrations (100 lmol/l)currents nor affects glutamatergic or GABAergic neuro-
transmission [23–26]. Thus, LTG may beside its action on were used to obtain more pronounced differences of cur-
rents; however, the same direction, but not magnitude,voltage-dependent sodium channels [5, 6] also modulate
neuronal L-type calcium channels. This is of special inter- of effects on potassium currents was also observed in
clinically relevant concentrations of 25 lmol/l. In thisest because calcium antagonistic actions are discussed in
treatment strategies of epilepsies [27] as well as in affective regard, most concentrations used in this in vitro model
correspond to therapeutic plasma levels of LTG.disorders [28].
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These extracellular experiments do not differentiate that LTG is a positive modulator of these currents. This
is a property of LTG which was previously described forbetween the types of calcium channels which may be
blocked by LTG and the possibility cannot be ruled out the inorganic substance zinc [34] and, for IA , from two
other antiepileptic drugs: valproate, tested in snail neu-that modulations of second messenger systems impinging
on calcium channel phosphorylation may be involved. rons [11] and CBZ, tested in neocortical cell cultures from
rats [12], whereas, to our knowledge, positive modulatorsMoreover, the reports in the literature are controversial.
Whereas Lees and Leach [30] describe the inhibitory of ID have not been described yet.
In conclusion, our experiments show effects of LTGeffects of 100 lmol/l LTG on presumptive calcium cur-
rents in cultured cortical rat neurons, Lang and Wang in a calcium-dependent model of epilepsy in extracellular
recordings and on fast potassium outward currents in[31] found no significant effect on L-type and T-type
currents in whole cell clamped pituitary cell lines. For patch clamp recordings. This indicates that the thera-
peutic efficacy of this drug does not only result from itsamygdala neurons, however, there are also recent reports
on the effects of LTG on N-type calcium channels [32]. action on voltage-dependent sodium channels with the
consequence of a decreased glutamate release, but alsoThe additive effect of subthreshold concentrations of
VERA and LTG in our experiments, however, also makes from other modulating effects on ion channels. With re-
spect to calcium, this is of interest, since (a) a disturbedaction via L-type calcium channels likely. Although pre-
synaptic effects of LTG on NMDA channels have been calcium ion homeostasis is discussed in the pathophysi-
ology of affective disorders [8]; (b) the use of calciumdescribed [33], actions through modulation of post-
synaptic NMDA channels by LTG appear less likely, as it antagonistic drugs is considered in the therapy of epilepsy
[28], and (c) clinical studies with organic calcium antago-shows no additive effects in subthreshold concentrations
with APV. Furthermore, it has been shown previously nists have shown therapeutic effects both in mania and
depression [35–38]. With respect to the modulation ofthat LTG does not to exert actions on NMDA stimulated
formation of cyclic GMP [5]. potassium currents by LTG, similar results have been
reported for valproate [11] and CBZ [12]; the implicationIntracellular recordings focused on another mecha-
nism of limiting excitation, which is strengthening the fast of this finding for the pathophysiology and treatment of
epilepsies or bipolar disorder, however, still has to bepotassium outward current. Our whole cell and voltage
clamp experiments in hippocampal CA1 neurons suggest determined.
.................................................................................................................................................................
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